Ruth Alon - 20 Feb 2026 Form 4 Insider Report for Silexion Therapeutics Corp (SLXN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
23 Feb 2026, 16:20:33 UTC
Prior SEC filing
31 Dec 2025
Next SEC filing
18 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Mirit Horenshtein Hadar, Attorney-in-fact

Key filing fact

Ruth Alon filed Form 4 for Silexion Therapeutics Corp (SLXN) on 23 Feb 2026.

Key facts

  • This page summarizes Ruth Alon's Form 4 filing for Silexion Therapeutics Corp (SLXN).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 23 Feb 2026, 16:20.

Change

  • Previous filing in this sequence was filed on 31 Dec 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001796386 Primary reporting owner

Alon Ruth

Relationship
Director
Address
C/O SILEXION THERAPEUTIC CORP, 12 ABBA HILLEL ROAD, RAMAT GAN, ISRAEL
Signature
/s/ Mirit Horenshtein Hadar, Attorney-in-fact
Signature date
23 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLXN transaction

Ordinary Shares

Award

Transaction value
$0
Shares
+9,091
Change %
+800%
Price
$0.000000
Shares after
10,228
Date
20 Feb 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLXN transaction Derivative

Stock Option (right to buy Ordinary Shares)

Award

Transaction value
$0
Shares
+10,685
Change %
Price
$0.000000
Shares after
10,685
Date
20 Feb 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
10,685
Exercise price
$1.65
Footnotes
F2, F3
SLXN holding Derivative

Stock Option (right to buy Ordinary Shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
935
Date
20 Feb 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
935
Exercise price
$18.90
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares"), in respect of the Reporting Person's services as a director of the Issuer. The grant was approved by the Issuer's board of directors.

Footnote F2

The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, in respect of the Reporting Person's services as a director of the Issuer, which grant was approved by the Issuer's board of directors.

Footnote F3

The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.

Footnote F4

There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .